ES2193401T3 - Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias. - Google Patents

Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias.

Info

Publication number
ES2193401T3
ES2193401T3 ES97942949T ES97942949T ES2193401T3 ES 2193401 T3 ES2193401 T3 ES 2193401T3 ES 97942949 T ES97942949 T ES 97942949T ES 97942949 T ES97942949 T ES 97942949T ES 2193401 T3 ES2193401 T3 ES 2193401T3
Authority
ES
Spain
Prior art keywords
agent
peptides suitable
therapeutic agent
autoimmunity diseases
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97942949T
Other languages
English (en)
Inventor
Gerhild Wildner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2193401T3 publication Critical patent/ES2193401T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A PEPTIDOS DERIVADOS DE LOS CAMPOS AL 1 O AL 2 DE HLA - B27 O QUERATINA HUMANA IV, ASI COMO AL USO DE PEPTIDOS ESPECIFICOS DERIVADOS DE LOS CAMPOS AL 1 O AL 2 DE HLA - B27 O QUERATINA HUMANA IV PARA EL DIAGNOSTICO Y TRATAMIENTO DE ENFERMEDADES AUTOINMUNES DEPENDIENTES DE LA HLA.
ES97942949T 1996-09-18 1997-09-18 Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias. Expired - Lifetime ES2193401T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19638108 1996-09-18

Publications (1)

Publication Number Publication Date
ES2193401T3 true ES2193401T3 (es) 2003-11-01

Family

ID=7806049

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97942949T Expired - Lifetime ES2193401T3 (es) 1996-09-18 1997-09-18 Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias.

Country Status (8)

Country Link
EP (1) EP0950065B1 (es)
JP (2) JP4615630B2 (es)
CN (1) CN1227263C (es)
AU (1) AU4459797A (es)
DE (1) DE59709363D1 (es)
ES (1) ES2193401T3 (es)
HK (1) HK1024006A1 (es)
WO (1) WO1998012221A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810099D0 (en) * 1998-05-11 1998-07-08 Isis Innovation Novel molecule and diagnostic method
IL154000A0 (en) * 2000-08-14 2003-07-31 Akzo Nobel Nv Use of antibodies against specific mhc-peptide complexes
WO2009090651A2 (en) * 2008-01-15 2009-07-23 Technion Research And Development Foundation Ltd. Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
WO2015000014A1 (en) 2013-07-01 2015-01-08 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5719064A (en) * 1992-08-31 1998-02-17 Oklahoma Medical Research Foundation Peptide diagnostics and therapeutics for spondyloarthropathies
AU1093995A (en) * 1993-11-10 1995-05-29 Board Of Trustees Of The Leland Stanford Junior University Surface membrane proteins and their effect on immune response

Also Published As

Publication number Publication date
CN1227263C (zh) 2005-11-16
EP0950065B1 (de) 2003-02-19
AU4459797A (en) 1998-04-14
JP2010235607A (ja) 2010-10-21
EP0950065A1 (de) 1999-10-20
DE59709363D1 (de) 2003-03-27
JP2001504451A (ja) 2001-04-03
HK1024006A1 (en) 2000-09-29
CN1237981A (zh) 1999-12-08
JP4615630B2 (ja) 2011-01-19
WO1998012221A1 (de) 1998-03-26

Similar Documents

Publication Publication Date Title
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
BR0208076A (pt) Células t cd4*cd25* reguladoras de sangue humano
ES2190803T3 (es) Iminas ciclicas como pesticidas.
AR012289A1 (es) UNA COMPOSICION COSMETICA PARA EL CUIDADO DE LA PIEL, METODOS COSMÉTICOS PARA REDUCIR, EVITAR O CONTROLAR LA SECRECION SEBACEA DE SEBOCITOS Y PARA PROTEGER A LA PIEL DE LA ACTIVIDAD DE LOS RADICALES LIBRES, Y USO COSMÉTICO DE DICHA COMPOSICIoN.
ES2176354T3 (es) Uso de nebivolol como agente anti-aterogenico.
PT912898E (pt) Metodo imunologico de deteccao de anticorpos dirigidos contra a transglutaminase (ttg) utilizacao de ttg para o diagnostico e controlo de terapia assim como agente farmaceutico oral contendo ttg
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
BR9712466A (pt) Aplicação de adamantanaminas ou compostos de estrutura análogo para combater o vìrus da doença de borna e para a profilaxia e tratamento de doenças emocionais e outras perturbaçoes ligadas com infecçoes do vìrus bd homem e animal
ES2193401T3 (es) Peptidos aptos como agente de diagnostico y agente terapeutico para las enfermedades autoinmunitarias.
BR0305018A (pt) Células dendrìticas tolerogênicas e usos terapêuticos para as mesmas
AR003901A1 (es) Composicion para el tratamiento de las fibras queratinicas que comprende al menos un polimero fijante y al menos un compuesto de tipo ceramida yprocedimientos.
ES2147453T3 (es) Antagonistas de adenosina, procedimiento para su preparacion y su uso como medicamentos.
ES2102284T3 (es) Composicion cosmetica que comprende una asociacion de ceramidas y su utilizacion.
ES2162919T3 (es) Piridilbisfosfonatos para uso como agente terapeutico.
PT928197E (pt) Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
DE69534024D1 (de) Peptide und pharmazeutische zusammensetzungen, die diese enthalten
BR9811796A (pt) Veìculo de terapia genética compreendendo tecido de revestimento dérmico
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
BR0009194A (pt) Composição do resorcinol
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi